Rankings Pharma & medtech Sanofi
Sanofi
79
15070100
A view of the same findings, not a new score. How it works
A strong score: the model found few serious problems, but analysts see limited upside from here.
Biggest deductions
- Product concentration−8
- Execution (late-stage pipeline)−7
- Future pipeline−3
Strengths
- Estimates+2
- Dividend and buybacks from FCF+2
- New launches+2
How the score is built
From 100 to 79, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 3 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 81.51 EUR
- Median analyst target
- 95.00 EUR
- Upside to median
- +16.6%
- Analysts
- 25
- Target range
- 78.00 – 107.20 EUR
- 52-week change
- −7%
- P/E (trailing)
- 23.6
- Forward P/E
- 8.8
- PEG
- 1.05
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 3 findings−7 of −30
- −2ROICROIC has been 8.1–10.2% in 2021–25 and is 9.1% TTM; ROE is only 5.7%. A modest return for a big pharma group.
- −2Quality of growthDupixent grew 37.6% to €5.2bn in Q2 and carries most of the group's 17.8% growth, while vaccines fell 4.7%.
- −3Future pipelineThe chief scientific officer calls the number of first-in-human starts 'abysmal'. The early pipeline must be rebuilt, and half of innovation will now be bought in, including late-stage assets (acquisitions of €10.2bn TTM).
Price
Today's multiples against the company's own history and its peers. · 1 finding−2 of −35
- −2Multiples vs own history and peersForward P/E 8.2 vs 10.0–12.5 in 2021–25; EV/EBITDA 7.7 vs 9.0–11.5; P/FCF 8.6 vs 11.2–15.9; dividend yield 5.7%. Below the bottom of its own range, but the discount reflects the patent expiry in 2031.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 5 findings−22 of −35
- −8Product concentrationDupixent was €5.2bn of €11.6bn (45%) of Q2 sales; the US compound patent expires in 2031.
- −7Execution (late-stage pipeline)Amlitelimab will not be filed globally (impairment of €952m), itepekimab, balinatunfib and belantamab have been stopped, and the FDA rejected tolebrutinib, citing a risk of serious liver injury and unclear efficacy.
- −2Governance and management changeThe CEO's contract was not renewed, the executive team was reorganised (July), and a new head of R&D started in September. He is now reviewing more phase 2 and 3 programmes.
- −2VaccinesVaccine sales fell 4.7% to €1.1bn in Q2 (influenza); TTM they are €7.8bn vs €8.3bn in 2024.
- −3MacroPolitical pressure on US drug prices (IRA negotiations and MFN policy) hits the US, the largest market.
Plus
Only documented strengths. · 4 findings+7 of +15
- +2Estimates2026 guidance raised to about 10% sales growth, with business EPS growing slightly faster than sales.
- +2Dividend and buybacks from FCFDividends (€4.9bn) and buybacks (€2.0bn) on a TTM basis are below FCF of €10.0bn; the €1bn buyback is completed, and the share count has fallen 2.5%.
- +2New launchesPharma launches (Ayvakit, ALTUVIIIO, Sarclisa and others) grew 48.3% to €1.3bn in Q2.
- +1Diversified baseA geographically spread business with seven regulatory approvals in H1, but the dependence on Dupixent weighs.
Caveats
What the score does not capture, or where the data is weak.
Dupixent was 45% of sales in Q2, and the US compound patent expires in 2031. New management and a new head of R&D are reviewing the late-stage pipeline, so several projects may be stopped. IFRS EPS (€0.29 in Q2) is far below business EPS (€2.09) because of impairments. Whether Dupixent is exposed to IRA price negotiations has not been examined. Q3 results 30/10.
Also in Pharma & medtech
The highest scores in the same industry.
